eligibility_summary
Adults 18–75, ECOG 0–1, histologically confirmed cHL, ≥2 prior therapies (transplant-ineligible/refused), life expectancy ≥3 mo, ≥1 measurable lesion >1 cm, prior therapy ≥4 wks ago with ≤grade 1 toxicity, ≥3 mo post autologous HSCT, adequate marrow, liver, renal, cardiac function. Exclude prior Chidamide+Decitabine+PD-1 or BV+PD-1, autoimmune needing immunosuppression, serious/uncontrolled illness/infection, recent/active GI bleed, organ allograft, pregnant/breastfeeding, compulsory detention.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 randomized, open-label trial in transplant-ineligible/refusing relapsed/refractory classical Hodgkin lymphoma compares: (1) Chidamide (oral benzamide HDAC inhibitor selective for HDAC1/2/3/10) + Decitabine (hypomethylating agent that depletes DNMT1) + an anti‑PD‑1 antibody, versus (2) standard Brentuximab Vedotin (anti‑CD30 antibody–drug conjugate delivering MMAE) + an anti‑PD‑1 antibody. Mechanisms: Chidamide promotes apoptosis, inhibits proliferation, and enhances immune surveillance via epigenetic acetylation, Decitabine increases tumor antigens and HLA, improves antigen processing and T‑cell infiltration, anti‑PD‑1 restores exhausted T‑cell activity, Brentuximab Vedotin targets CD30 on Reed–Sternberg cells, causing microtubule disruption. Targets/pathways: HDAC1/2/3/10, DNMT1/DNA methylation, PD‑1/PD‑L1 on T cells, CD30 on tumor cells, antigen presentation (HLA). Primary endpoint: PFS.